KalVista Pharmaceuticals, Inc. (LSX:A2DG49) Financings

KalVista Pharmaceuticals, Inc.

Financings

RaiseDate
Convertible notes
Closed: US$144M raised
Use of proceeds: Continue advancing the global launch strategy for EKTERLY and building long-term growth
Nov 10, 2025
Convertible Senior Notes due 2031
Announced: US$110M
Use of proceeds: Working capital and general corporate purposes, including the commercialization of EKTERLY; possibly investments in or acquisitions of other companies or products
Sep 24, 2025

Read by 6ix AI from the company's releases